"Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024" "Dupixent also had a strong performance in 2024, with global net sales hitting $3.2B in Q4 alone" Reply ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this ...

A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents to thwart ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents ...

On July 16, 2024, the UPC issued its first-ever revocation judgment, invalidating a key patent owned by Amgen Inc. Back in June 2023, Amgen filed an infringement action against Regeneron ...

i US Patent No. 8,829,165 (Amgen) 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following ...

As part of this, he manages patent litigation related to Regeneron's EYLEA product, a prescription medicine intended to treat wet age-related macular degeneration and other conditions. Gesior tells ...

Oct 4 - Biotech company Regeneron Pharmaceuticals (REGN.O), opens new tab lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 ...

Regeneron struck back with its suit in 2022, arguing that the proposed copycat steps on 24 of its patents. The complaint was later trimmed to three, according to Bloomberg .

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court.